Cargando…
Extracorporeal Immunomodulation Treatment and Clinical Outcomes in ICU COVID-19 Patients
To evaluate safety and clinical outcomes of extracorporeal immunomodulation treatment with a selective cytopheretic device (SCD) in COVID-19 ICU patients with multiple organ failure. DESIGN: Two-center, prospective, single-arm treatment clinical trial. SETTING: ICUs at two academic medical centers b...
Autores principales: | Yessayan, Lenar T., Neyra, Javier A., Westover, Angela J., Szamosfalvi, Balazs, Humes, H. David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126516/ https://www.ncbi.nlm.nih.gov/pubmed/35620768 http://dx.doi.org/10.1097/CCE.0000000000000694 |
Ejemplares similares
-
Use of extracorporeal immunomodulation in a toddler with hemophagocytic lymphohistiocytosis and multisystem organ failure
por: Goldstein, Stuart L., et al.
Publicado: (2022) -
Innovations in CKRT: individualized therapy with fewer complications
por: Szamosfalvi, Balazs, et al.
Publicado: (2020) -
Translation of immunomodulatory therapy to treat chronic heart failure: Preclinical studies to first in human
por: Humes, H. David, et al.
Publicado: (2023) -
Regional citrate anticoagulation “non-shock” protocol with pre-calculated flow settings for patients with at least 6 L/hour liver citrate clearance
por: Yessayan, Lenar, et al.
Publicado: (2021) -
Impact of Acute Kidney Injury and CKD on Adverse Outcomes in Critically Ill Septic Patients
por: Neyra, Javier A., et al.
Publicado: (2018)